Clinical trials and evidence
Clinical trials and real-world evidence support evidence-based medicine in healthcare, playing a pivotal role in validating and advancing medical treatments and interventions. Clinical trials assess the efficacy and safety of new drugs and therapies, with real-world evidence providing data to inform clinical and regulatory decisions based on empirical data.
Top Stories
-
News
09 Jun 2026
Will obesity drugs save Pfizer from its post-COVID slump?
With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity pipeline. Continue Reading
-
News
08 Jun 2026
Structure's GLP-1 obesity pill could compete with others on the market
Phase 2 data suggests Structure Therapeutics' GLP-1 pill, aleniglipron, could be a potential competitor in the growing market for oral obesity treatments, analysts say. Continue Reading
-
News
13 Oct 2022
J&J Ulcerative Colitis Clinical Trial Produces High Rate of Remission
A Phase 2 clinical trial found that nearly 50% of patients suffering from ulcerative colitis reached clinical remission with a combination of guselkumab and golimumab. Continue Reading
-
News
11 Oct 2022
Walmart Launches Clinical Research Mission
In a press statement released today, Walmart launched its clinical research mission focused on marginalized communities. Continue Reading
-
News
07 Oct 2022
COVID-19 Vaccination Alters Menstrual Cycle Length
In a global retrospective cohort study, researchers found that COVID-19 vaccination alters menstrual cycle length. Continue Reading
-
News
04 Oct 2022
FDA Approves Drug for Open-Angle Glaucoma and Ocular Hypertension
On September 26, 2022, the FDA approved a new drug — in the form of eyedrops — by Santen to treat open-angle glaucoma and ocular hypertension. Continue Reading
-
News
30 Sep 2022
Fish Oil Supplements Associated with Risk of Atrial Fibrillation
A recent publication in the European Journal of Preventative Cardiology found that habitual use of fish oil supplements is associated with an increased risk of atrial fibrillation. Continue Reading
-
News
21 Sep 2022
How a New Antiviral Therapy May Prevent COVID-19 Transmission
Researchers at the Gladstone Institutes have developed an intranasal antiviral therapy that may prevent COVID-19 transmission. Continue Reading
-
News
19 Sep 2022
Pregnant and Lactating Individuals Tolerate COVID Vaccine Boosters
A recent analysis published in JAMA Network Open found that pregnant and lactating individuals tolerate COVID vaccine boosters and third vaccine doses well. Continue Reading
-
News
16 Sep 2022
FDA and NIH Launch Partnership for Rare Neurodegenerative Diseases
On September 14, 2022, the FDA announced that it was launching a partnership with the NIH for rare neurodegenerative diseases called the Critical Path for Rare Neurodegenerative Diseases (CP-RND). Continue Reading
-
News
15 Sep 2022
Amgen’s Immunotherapy for Lung Cancer Reduces Disease Progression by 34%
Sotorasib, sold under the brand name Lumakras, improved progression-free survival by 34% compared to chemotherapy in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). Continue Reading
-
News
15 Sep 2022
Biden Administration Appoints Renee Wegrzyn as Director of the ARPA-H
On September 12, 2022, the Biden Administration appointed Renee Wegrzyn, current vice president of business at Ginkgo Bioworks, director of the ARPA-H. Continue Reading
-
Answer
14 Sep 2022
Biosimilars Have Saved $12.6 Billion in the US between 2014 and 2022
A recent survey published by Vizient analyzed the adoptability of biosimilars and highlighted the benefits, including $12.6 billion saved between 2014 and 2022. Continue Reading
-
News
14 Sep 2022
Democratizing Access to Clinical Trials through Remote Patient Monitoring
Telehealth technologies such as remote patient monitoring and wearable devices hold the key to democratizing access to clinical trials. Continue Reading
-
News
13 Sep 2022
Psilocybin-Assisted Psychotherapy Reduces Heavy Drinking
A recent publication in JAMA Psychiatry found that psilocybin-assisted psychotherapy reduces the number of heavy drinking days in patients with alcohol use disorder. Continue Reading
-
News
12 Sep 2022
Glucocorticoids Alter Brain Volume and White Matter Microstructure
A recent study published in BMJ Open found that systemic and inhaled use of glucocorticoids altered brain volume and reduced white matter microstructure integrity. Continue Reading
-
News
08 Sep 2022
Paxlovid Advantageous for Elderly COVID-19 Patients, Ineffective in Younger Adults
An Israeli study found that patients over 65 years of age treated with Paxlovid, Pfizer’s protease inhibitor, were significantly less likely to be hospitalized or die due to COVID-19 infection. Continue Reading
-
News
07 Sep 2022
Stroke Prevention Study to Analyze Benefits of Wearable Devices
A study at the Center for Arrhythmia Research at Northwestern University received a grant to fund plans to analyze the benefits of wearable devices, such as the Apple Watch, in stroke prevention. Continue Reading
-
News
29 Aug 2022
Integrating Real-World and Clinical Trial Data to Improve Patient Outcomes
Integrating real-world data from patient monitoring devices and randomized clinical trial data could improve patient care outcomes, boost clinical trial efficiency, and reduce the cost of clinical studies. Continue Reading
-
News
16 Aug 2022
Hormonal Male Birth Control Product Reaches Late-Phase Clinical Trials
A recent spotlight by the National Institute of Child Health and Human Development (NICHD) highlighted the first hormonal male birth control clinical trial to reach late phases. Continue Reading
-
News
12 Aug 2022
Fourth COVID Shot Reduced the Risk of Infection by 12.9%
A recent study in JAMA Network Open found that a fourth COVID shot reduced the risk of SARS-CoV-2 infection by 12.9% compared to people who only had a three-dose series. Continue Reading
-
News
10 Aug 2022
Antibiotic Overprescription Is Associated with Worse CKD Outcomes
A publication in JAMA Open Network reported that higher dose prescriptions of the antibiotic fluoroquinolone are associated with an increased risk of adverse CKD outcomes. Continue Reading
-
Answer
09 Aug 2022
Addressing Racial Inequities in US Cancer Clinical Trials
New research shows that African American and Latin American populations lacked representation in US cancer clinical trials, underscoring an access to care issue. Continue Reading
-
News
08 Aug 2022
COVID-19 Vaccination Reduced the Risk of Reinfection by Approximately 50%
A recent investigation published in JAMA found that the COVID-19 vaccination reduced the risk of SARS-CoV-2 reinfection by 50%. Continue Reading
-
News
05 Aug 2022
Fall COVID Vaccine Boosters Could Prevent over 100,000 Deaths
A recent analysis by the Commonwealth Fund estimates that a fall COVID vaccine booster campaign could prevent over 100,000 deaths. Continue Reading
-
News
01 Aug 2022
Astellas and Seagen Announce Results on a Drug for Urothelial Cancer
On July 26, 2022, Astellas and Seagen announced results for a combined drug regimen to treat urothelial cancer in patients unable to receive cisplatin-based chemotherapy. Continue Reading
-
News
29 Jul 2022
Paxlovid Reduces Patient Hospitalization Risk by 5 Times
A recent study released by Epic Research found that COVID-19 patient hospitalization risk decreased by five times when taking Paxlovid. Continue Reading
-
News
28 Jul 2022
Decreased COVID-19 Vaccination Rates: A Pediatric Health Risk
A recent article from the Kaiser Family Foundation found that pediatric COVID-19 vaccination rates have decreased, which may have implications for health risks. Continue Reading
-
News
27 Jul 2022
Increased Rates of Non-Opioid Prescription Following CDC Guidelines
A JAMA publication earlier this year found an increased percentage of non-opioid pain medication prescriptions following the 2016 CDC guidelines. Continue Reading
-
News
26 Jul 2022
Global Vaccination Coverage Dropped 5% in 2021
A recent statement from the WHO on immunization coverage found that vaccination rates dropped 5% in 2021. Continue Reading
-
News
25 Jul 2022
FDA Grants Abbott Permission to Investigate DBS in Managing Depression
In a July 12 press release, Abbott announced that the FDA granted the company a Breakthrough Device Designation to investigate the use of DBS in managing depression. Continue Reading
-
News
22 Jul 2022
Aid Access Discusses Making Abortion Pill Available as Contraception
In a recent interview, Rebecca Gomperts, MD, founder of Aid Access, highlighted plans to make abortion pills available as a weekly contraceptive. Continue Reading
-
News
19 Jul 2022
Verve Doses First Patient with Investigational Gene-Editing Medicine
On July 12, 2022, Verve Therapeutics announced the start of phase 1b clinical trials in which they dosed the first human with an investigational in vivo base gene-editing medicine. Continue Reading
-
News
18 Jul 2022
Orexo Pharmaceuticals Announces Nasal Adrenaline Clinical Development
A recent press release from Orexo Pharmaceuticals announced their plans to begin clinical development on a nasal adrenaline rescue medication. Continue Reading
-
News
15 Jul 2022
Decentralization Tools May Improve Cancer Clinical Trial Enrollment
A recent investigation concluded that decentralizing clinical trials using remote technology and additional tools may help improve cancer clinical trial enrollment. Continue Reading
-
News
13 Jul 2022
Psychotropic Medications Linked to an Increased Risk of Parkinson’s
A recent study found that some psychotropic medications may be linked to an increased Parkinson’s disease risk. Continue Reading
-
News
11 Jul 2022
Decibel Therapeutics Announces Results of DB-020 Clinical Trial
Decibel Therapeutics announced positive results from early DB-020 clinical trial phases in cancer patients treated with cisplatin. Continue Reading
-
News
06 Jul 2022
FDA Approves New Treatment for Large B-Cell Lymphoma
On June 24, the FDA approved a new large B-cell lymphoma treatment as a second line of defense for patients. Continue Reading
-
News
05 Jul 2022
FDA Approves New Weight Management Drug for Kids over 12
The FDA recently approved Qsymia, a chronic weight management drug, for pediatric patients over 12. Continue Reading
-
News
01 Jul 2022
HPV Vaccine Rates Increase among Adolescents
According to a recent American Academy of Pediatrics publication, human papillomavirus (HPV) vaccine rates have increased among adolescents. Continue Reading
-
News
30 Jun 2022
Radiologists Look for Ways to Conserve amidst the Dye Shortage
With the current dye shortage that began in April 2022, a JAMA letter was published discussing ways radiologists can conserve. Continue Reading
-
News
29 Jun 2022
Women Are Underrepresented in Clinical Trials, Leading to Health Inequity
A recent study published in Contemporary Clinical Trials found that women were underrepresented in clinical trials, which may be contributing to health inequity. Continue Reading
-
News
23 Jun 2022
Vagus Nerve Stimulation Augments Behaviors in Epilepsy Patients
Vagus Nerve Stimulation Augments Behaviors in Epilepsy Patients Continue Reading
-
News
22 Jun 2022
FDA Approved Weight-Management Treatment for Bardet–Biedl Syndrome
Late last week, the FDA approved a weight-management treatment for patients with Bardet–Biedl Syndrome. Continue Reading
-
News
10 Jun 2022
CDC Report Links People Seeking Substance Misuse Treatment to Psychiatric Issues
A 2019 CDC study links people seeking treatment for substance misuse to moderate-to-severe psychiatric issues across multiple biopsychosocial domains. Continue Reading
-
News
09 Jun 2022
FDA Recommends Emergency Use for Novavax Coronavirus Vaccine
An FDA advisory committee voted unanimously to recommend emergency use authorization for the protein-based Novavax coronavirus vaccine. Continue Reading
-
News
08 Jun 2022
Researchers Discover Promising Compound That Kills Hard-to-Treat Cancer Cells
Researchers from the University of Texas Health Science Center have discovered a promising compound that kills hard-to-treat cancer cells in culture and animal models. Continue Reading
-
News
07 Jun 2022
Pfizer-BioNTech’s Expanding Coronavirus Vaccine FDA Approval
Initially marketed as Comirnaty, Pfizer and BioNTech’s coronavirus vaccine has slowly expanded its reach and is eyeing a final stage of FDA approval in the coming months. Continue Reading
-
News
03 Jun 2022
Study Finds Vaccination During Pregnancy Decreases Baby’s COVID-19 Risk
A CDC study finds that vaccination during pregnancy decreases the risk of COVID-19 in infants for the first 6 months of life. Continue Reading
-
News
02 Jun 2022
Novartis Gains FDA Approval for Follicular Lymphoma Cell Therapy
FDA issued accelerated approval for Kymriah after the drug achieved an 86% response rate in phase II clinical trials. Continue Reading
-
News
01 Jun 2022
Academia Partners with Pharma to Discover New SARS-CoV-2 Drug Treatments
Academia and pharmaceutical experts have partnered to form a regional drug accelerator to develop novel antiviral treatments to combat SARS-CoV-2 and other viruses. Continue Reading
-
News
31 May 2022
Coronavirus Rebound After Pfizer’s Paxlovid Oral Antiviral Drug
The Centers for Disease Control and Prevention (CDC) issued a health advisory to warn providers of the potential for coronavirus recurrence after Paxlovid use. Continue Reading
-
News
26 May 2022
FDA Approves First Drug for Chronic Disease Eosinophilic Esophagitis
Monoclonal antibody Dupixent was approved after a successful double-blind clinical trial. Continue Reading
-
News
19 May 2022
FDA Lifts Clinical Hold on Gilead’s HIV Treatment, Lenacapavir
FDA based its decision following a review of Gilead’s data on the storage and compatibility of HIV treatment lenacapavir injection with an alternative vial made from aluminosilicate glass. Continue Reading
-
News
18 May 2022
Bristol Myers Squibb’s Drug Effective in Plaque Psoriasis Patients
The two-year results from the POETYK PSO long-term extension trial showed that plaque psoriasis patients maintained clinical efficacy with deucravacitinib. Continue Reading
-
News
16 May 2022
Novo Nordisk, Flagship to Develop Rare Disease Treatments
The collaboration will provide access to innovation and leverage the technology platforms of multiple biotech companies to create a portfolio of medicines for rare diseases. Continue Reading
-
News
12 May 2022
Real-World Evidence Shows Pfizer’s Ibrance Improves Breast Cancer
Real-world evidence shows that Ibrance combined with an aromatase inhibitor (AI) improved overall survival in post-menopausal women and in men with HR+ HER2– metastatic breast cancer. Continue Reading
-
News
11 May 2022
Bristol Myers Ends Clinical Program for Combination Drug Therapy
All ongoing studies of the combination drug therapy, bempegaldesleukin and Opdivo, will be discontinued based on a pre-planned analysis of two late-stage clinical trials. Continue Reading
-
News
10 May 2022
Novartis' Antibody Boosts Survival for Squamous Cell Carcinoma
The Phase 3 study found that the IgG4 anti-PD-1 monoclonal antibody improved progression-free survival, objective response rate, duration of response, and safety. Continue Reading
-
News
10 May 2022
Gilead, Dragonfly to Advance Immunotherapies in Oncology
Under the terms of the agreement, Dragonfly will grant Gilead an exclusive, worldwide license for the 5T4-targeting investigational immunotherapy program, DF7001, in oncology. Continue Reading
-
News
09 May 2022
Eli Lilly's Obesity Drug Elicits 22.5% of Weight Loss in Adults
The overall average body weight reductions in the obesity drug group were 15% in the 5 mg group, 19.5% in the 10 mg group, 20.9% in the 15 mg group, and 3.1% in the placebo group. Continue Reading
-
News
09 May 2022
Roche’s Drug Improves Infants with Type 1 Spinal Muscular Atrophy
The FIREFISH study found that 91% of infants treated with Roche’s Evrysdi were alive after three years of treatment and continued to improve or maintain motor functions. Continue Reading
-
News
05 May 2022
FDA Approves AstraZeneca’s Drug for Generalized Myasthenia Gravis
Other recent FDA approvals include Bristol Myer Squibb’s drug to treat adults with obstructive hypertrophic cardiomyopathy and Mycovia Pharmaceuticals’ drug for vulvovaginal candidiasis. Continue Reading
-
News
03 May 2022
FDA Accepts AstraZeneca BLA for Hepatocellular Carcinoma Antibody
FDA based the BLA for the hepatocellular carcinoma antibody on a Phase 3 trial, which found that patients treated experienced a 22% reduction in the risk of death versus sorafenib. Continue Reading
-
News
03 May 2022
Pfizer Reports Positive Phase 2 Data for Lyme Disease Vaccine
The Lyme disease vaccine candidate elicited a similar safety and tolerability profile in patients aged 5–17-years old as adult participants in previous studies. Continue Reading
-
News
02 May 2022
Sandoz Launches Generic Drug Combination for Ocular Hypertension
The generic drug combination eyedrop, an AB-related generic equivalent to AbbVie’s COMBIGAN, is immediately available to patients via retail pharmacies. Continue Reading
-
News
29 Apr 2022
FDA Accepts Application for GSK’s Chronic Kidney Disease Drug
The ASCEND Phase 3 clinical trial program found that GSK’s drug improved or maintained hemoglobin (Hb) within the target level for all chronic kidney disease patients. Continue Reading
-
Feature
27 Apr 2022
Exploring Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs)
Selective serotonin reuptake inhibitors are the most commonly prescribed medications for treating major depressive disorder, anxiety disorders, and other psychological conditions. Continue Reading
-
News
25 Apr 2022
FDA Grants Priority Review for Non-Small Cell Lung Cancer Drug
AstraZeneca and Daiichi Sankyo's non-small cell lung cancer drug, Enhertu, elicited an objective response rate of 54.9% and a partial response rate of 53.8%. Continue Reading
-
News
21 Apr 2022
Sanofi's BTK Inhibitor Effective in Immune Thrombocytopenia Patients
In the Phase 1/2 clinical trial, 24 of the 60 pre-treated immune thrombocytopenia patients enrolled in the study achieved the primary endpoint with any dosing regimen. Continue Reading
-
News
21 Apr 2022
FDA Lifts Hold on Gilead’s MDS, AML Clinical Trials
FDA lifts the partial hold placed on clinical trials evaluating Gilead’s magrolimab combined with azacitidine in myelodysplatic syndrome (MDS) and acute myeloid leukemia (AML) patients. Continue Reading
-
Feature
20 Apr 2022
Major Milestones in Medicine, Drug Development in Recorded History
The past few centuries have witnessed several revolutionary milestones in modern medicine and drug development that have drastically improved human health. Continue Reading
-
News
19 Apr 2022
Moderna Doses Participants in Study of Two Influenza mRNA Vaccines
The trial will evaluate the safety, reactogenicity, and immunogenicity of a single dose of Moderna's influenza mRNA vaccine candidates in 560 adults 18 years of age and older. Continue Reading
-
News
14 Apr 2022
Eli Lilly's Retevmo Helps Non-Small Cell Lung Cancer Patients
In the Phase 1/2 trial, the objective response rate was 61.1% in non-small cell lung cancer patients previously treated with platinum chemotherapy and 84.1% in treatment-naïve patients. Continue Reading
-
News
14 Apr 2022
Pfizer to Acquire BioPharma Company to Develop RSV Therapeutics
Pfizer will acquire ReViral and its portfolio of promising RSV therapeutics, including sisunatovir, designed to block the fusion of the RSV virus to the host cell. Continue Reading
-
News
13 Apr 2022
Michigan Blue Launches Pharmacogenomics Precision Medicine Program
Blue Care Network recently announced the launch of Michigan’s first end-to-end pharmacogenomics precision medicine program, Blue Cross Personalized Medicine. Continue Reading
-
News
07 Apr 2022
New Toolkit Supports Digital Endpoints in Drug Development
DiMe, Biogen, Eli Lilly, Pfizer, and other top pharma companies launched a toolkit to ensure that organizations develop digital endpoint evidence in an acceptable way during drug development. Continue Reading
-
News
06 Apr 2022
Roche’s Small Cell Lung Cancer Antibody Fails in Phase 3 Trial
In the Phase 3 clinical trial, small cell lung cancer patients who received the antibody did not achieve overall survival and are unlikely to reach statistical significance at the final analysis. Continue Reading
-
News
05 Apr 2022
AstraZeneca to Share New Data on Oncology Treatment Landscape
AstraZeneca will share new potential oncology treatments, which span its immuno-oncology (IO), DNA damage response (DDR), and antibody–drug conjugate (ADC) scientific platforms. Continue Reading
-
News
04 Apr 2022
Merck’s CMV Drug Lowers Reactivation by 88% After Cell Transplant
Merck’s CMV drug, Prevymis, lowered the chance for clinically significant CMV infection by 91% 100 days after allogeneic hematopoietic cell transplant (alloHCT). Continue Reading
-
News
04 Apr 2022
Pfizer’s S1P Modulator Drug Helps Ulcerative Colitis Patients
Ulcerative colitis patients achieved statistically significant improvements in the co-primary endpoints of clinical remission at weeks 12 and 52 compared to placebo in a Phase 3 trial. Continue Reading
-
News
29 Mar 2022
Pfizer’s Ulcerative Colitis Drug Helps Patients in Phase 3 Study
The global Phase 3 study found that the ulcerative colitis treatment improved clinical remission at week 12 and all key secondary endpoints. Continue Reading
-
News
29 Mar 2022
Vivalink's Biometrics Data Platform Monitors Oncology Patients
A clinical trial of 80 oncology patients undergoing outpatient intermediate-risk chemotherapy regimens will leverage Vivalink's biometrics data platform to detect neutropenic fever events. Continue Reading
-
News
28 Mar 2022
Moderna Will Expand mRNA Vaccine Pipeline Through 2 New Programs
Moderna will launch a respiratory combination vaccine program to target three viruses causing respiratory disease in adults and a program to develop an mRNA vaccine candidate for HCoVs. Continue Reading
-
News
24 Mar 2022
Thermo Fisher to Invest $97M to Expand Drug Development Efforts
Over the next three years, Thermo Fisher will add nearly 150,000 square feet and over 500 new employees to its Richmond, Virginia laboratory to further drug development. Continue Reading
-
News
24 Mar 2022
Pfizer Submits for EUA of Additional COVID-19 Vaccine Booster
In other COVID news, Roche provides molecular testing solutions to identify SARS-CoV-2 variants and Moderna will provide Switzerland with an additional 7 million COVID-19 vaccine doses. Continue Reading
-
News
23 Mar 2022
Keytruda Boosts Survival Rate for Non-Small Cell Lung Cancer
The randomized Phase 3 trial found that Merck’s Keytruda decreased the risk of disease recurrence or death by 24% compared to placebo in non-small cell lung cancer patients. Continue Reading
-
Feature
22 Mar 2022
How Regulation Stymies Medical Research of Controlled Substances
Barriers to medical research constructed by federally controlled substance scheduling and classification stifle the development of safe and effective products aimed to improve overall human health. Continue Reading
-
News
22 Mar 2022
AstraZeneca Launches R&D Challenge to Advance Drug Discovery
MD students, PhD students, and postdoctoral researchers worldwide can propose their innovative ideas and help boost drug discovery across AstraZeneca’s core disease areas. Continue Reading
-
News
21 Mar 2022
Boehringer Ingelheim Halts Chronic Kidney Disease Trial
Boehringer Ingelheim will stop the Phase 3 EMPA-KIDNEY trial after clear positive efficacy of empagliflozin in adults with chronic kidney disease. Continue Reading
-
News
21 Mar 2022
Moderna Doses First Patient in HIV mRNA Vaccine Clinical Trial
The primary hypothesis is that the HIV-uninfected individuals will tolerate the HIV envelope trimer mRNA vaccines and elicit autologous neutralizing antibodies. Continue Reading
-
News
17 Mar 2022
Civica to Manufacture Lower-Priced Insulin for Diabetes Patients
The availability of three affordable insulins will benefit diabetes patients forced to choose between life-sustaining medicines and living expenses. Continue Reading
-
News
17 Mar 2022
Pfizer’s C. Difficile Vaccine Misses Primary Endpoint in Trial
Pfizer’s C. difficile vaccine did not meet its primary endpoint in a Phase 3 trial after COVID-19 forced the company to accrue fewer cases of CDI over a longer period than initially intended. Continue Reading
-
News
16 Mar 2022
Novo Nordisk Expands Collaboration in Oral Drug Delivery Tech
The collaboration in oral drug delivery technologies now extends through 2026, expanding the scope to include the integration of bioelectronics, biosensors, and delivery devices. Continue Reading
-
News
14 Mar 2022
Gilead’s Trodelvy Helps HR/HER2 Metastatic Breast Cancer Patients
Researchers targeted a 30% reduction in the risk of disease progression or death in breast cancer patients in the Phase 3 TROPiCS clinical trial. Continue Reading
-
Feature
09 Mar 2022
Understanding the Value, Complexity of Clinical Trials in the US
Clinical trials in the US study new drug developments and evaluate the effects in humans. Continue Reading
-
News
07 Mar 2022
AstraZeneca, Alexion, Neurimmune to Develop Rare Disease Antibody
The monoclonal antibody, NI006, is currently Phase 1b development to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a generally underdiagnosed rare disease. Continue Reading
-
Feature
04 Mar 2022
Understanding US Food and Drug Administration (FDA) Approval Processes
The FDA approvals process is complex and time-consuming, taking an average of 12 and 7 years for drugs and devices, respectively. Continue Reading
-
News
02 Mar 2022
CHMP Recommends Pfizer, Biohaven’s Generic Drug for Migraine Attacks
In all studies, 75 milligrams of generic drug rimegepant was safe and well-tolerated with rates of adverse events similar to placebo. Continue Reading
-
News
01 Mar 2022
ACIP Recommends Pfizer’s TBE Vaccine For Individuals Most At Risk
ACIP recommends Pfizer’s TBE vaccine for individuals one year and older who travel or move to TBE endemic areas or have extensive exposure to ticks. Continue Reading
-
News
01 Mar 2022
Moderna, Thermo Fisher to Boost mRNA Vaccine Manufacturing
Thermo Fisher will provide capacity for a range of aseptic fill/finish services for Moderna’s COVID-19 vaccine and mRNA vaccine pipeline to increase capacity in the US. Continue Reading
-
News
28 Feb 2022
Moderna Expands mRNA Vaccine Pipeline for HSV, VZV, Cancer
Moderna’s expansion includes three new development programs for an HSV-2 vaccine, a VZV vaccine, and a checkpoint mRNA vaccine for cancer. Continue Reading